Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease

Diabetic kidney disease is a major cause of end-stage renal failure worldwide, driven by hyperglycaemia, haemodynamic stress and pro-inflammatory pathways. Aldosterone acting via the mineralocorticoid receptor (MR) promotes sodium retention, oxidative stress, inflammation and fibrosis in the glomerulus and tubulointerstitium. Mineralocorticoid receptor antagonists (MRAs) counteract these effects, reducing albuminuria, preserving glomerular filtration rate (GFR) and attenuating the progression of renal fibrosis. Early steroidal MRAs such as spironolactone and eplerenone have demonstrated antiproteinuric benefits but are limited by off-target effects and hyperkalaemia. The development of highly selective non-steroidal MRAs has revitalised this therapeutic class, offering improved safety and efficacy profiles. Ongoing research aims to refine patient selection, optimise dosing strategies and combine MRAs with renin-angiotensin system inhibitors or sodium–glucose cotransporter-2 inhibitors to achieve maximal renal protection in people with type 2 diabetes.

Research from Nature Portfolio

A pooled participant-level analysis of three large trials evaluated finerenone, a non-steroidal MRA, in patients with type 2 diabetes and cardiorenal comorbidities. Over a median follow-up of nearly three years, finerenone reduced the composite kidney outcome—encompassing kidney failure, sustained decline in GFR and renal death—by approximately 20 per cent compared with placebo, alongside a significant reduction in hospitalisations for heart failure. The analysis also demonstrated a modest but statistically significant lower risk of all-cause mortality. Finerenone was generally well tolerated, with hyperkalaemia rates manageable under close monitoring. These findings extend earlier data on albuminuria reduction and underscore the clinical impact of selective MR antagonism in diabetic kidney disease.

Mineralocorticoid Receptor Antagonism in Diabetic Kidney Disease publication trend

The graph below shows the total number of articles in mineralocorticoid receptor antagonism in diabetic kidney disease across all publications each year (not limited to Nature Index journals).

Technical terms

Mineralocorticoid receptor (MR): Intracellular receptor activated by aldosterone that regulates sodium retention, inflammation and fibrotic signalling in the kidney.

Mineralocorticoid receptor antagonist (MRA): A drug that blocks MR activation, thereby reducing sodium reabsorption, inflammation and fibrosis.

Non-steroidal MRA: A newer class of MRAs with non-steroidal structure, offering enhanced receptor selectivity and reduced off-target effects.

Albuminuria: The presence of albumin in the urine, serving as an early marker of kidney damage in diabetes.

Hyperkalaemia: An elevated serum potassium concentration that can result from MR blockade and impair cardiac function if unmonitored.

Glomerular filtration rate (GFR): A measurement of how much blood the kidneys filter per minute, used to assess renal function.

References

1. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes. Nature Medicine (2024).
2. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrology (2016).
3. Novel non‐steroidal mineralocorticoid receptor antagonists in cardiorenal disease. British Journal of Pharmacology (2022).
4. Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study. Hypertension Research (2019).